Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01725061 · ClinicalTrials.gov registry record

Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis

A clinical trial, sponsored by Emory University.

Completed
Registry status
80
Enrollment target

NCT01725061 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 80 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01725061 has completed, sponsored by Emory University.

COMPLETED
Registry status
80 participants
Enrollment target

Study Summary

Acute lung injury (ALI) is an often deadly form of respiratory failure caused by inflammation. The widespread injury to the lungs involves a build-up of fluid in the lungs that results in damage to the lungs and a decreased ability of the lungs to function properly. There is currently no specific treatment for ALI; and of the 200,000 cases reported in the US yearly, about 40% will die. Some patients may have other conditions that could change the risk of developing ALI. For example, it has been reported that patients who have septic shock have a lower chance of developing ALI if they also have diabetes mellitus (diabetes). Septic shock is a type of infection that causes overwhelming inflammation to occur throughout the body; it increases the chances that a person will develop ALI. The reason diabetics are less likely to develop ALI is unclear and deserves further investigation. The investigators believe that it may be explained by differences in the way certain cells that are involved in inflammation function in the lungs. The investigators plan on looking at the relationship between the wide-spread inflammation that occurs within the bodies of diabetic and non-diabetic patients with an increased chance of developing ALI \[sepsis\]. To study this relationship, we will identify patients who fit the requirements of the study. The investigators will obtain blood samples and lung washings from these patients. The lung washings will be obtained by injecting clean salt water into the lungs through a tube and then pulling the water back out. When the sterile water is removed, some cells from the lungs also are removed and they can then be used for further lab studies. Determining how diabetes may change a patient's chance of developing ALI may uncover useful information that may help prevent or treat ALI in all patients at risk.

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2009-12
Est. Completion 2012-09

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT01725061

The ClinicalTrials.gov registry entry for NCT01725061 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01725061 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01725061 about?

NCT01725061 is a clinical study titled "Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis". Acute lung injury (ALI) is an often deadly form of respiratory failure caused by inflammation. The widespread injury to the lungs involves a build-up of fluid in the lungs that results in damage to the lungs and a decreased ability of the lungs to function properly. There is currently no specific tr...

What is the current status of trial NCT01725061?

This trial is currently completed. The enrollment target is 80 participants. The study started on 2009-12. Estimated completion is 2012-09.

Who is sponsoring clinical trial NCT01725061?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.